Enhancement effect of P-gp inhibitors on the intestinal absorption and antiproliferative activity of bestatin

European Journal of Pharmaceutical Sciences

Volumn 50, Issue 3-4, 2013, Pages 420-428

  Huo, Xiaokui ^a   Liu, Qi ^a   Wang, Changyuan ^a   Meng, Qiang ^a   Sun, Huijun ^a   Peng, Jinyong ^a   Ma, Xiaochi ^a   Liu, Kexin ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Antiproliferative activity; Bestatin; Intestinal absorption; P gp

Indexed keywords

BESTATIN; CILOSTAZOL; CYCLOSPORIN A; DIGOXIN; DOXORUBICIN; GLYCOPROTEIN P INHIBITOR; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; VERAPAMIL;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CELL STRAIN K 562; CELL STRAIN U937; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC 50; IMMUNOMODULATION; IN VITRO STUDY; INTESTINE ABSORPTION; LIQUID CHROMATOGRAPHY; MDCK CELL; NONHUMAN; PRIORITY JOURNAL;

ADR; ADRIAMYCIN; ANTIPROLIFERATIVE ACTIVITY; AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE; AUC; BESTATIN; CLP; CSA; CYCLOSPORIN A; DDI; DRUG-DRUG INTERACTION; H(+)/PEPTIDE TRANSPORTER; INTESTINAL ABSORPTION; KRB; KREBS-RINGER BUFFER; MDR; MRP2; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; OAT; OCT; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; P-GLYCOPROTEIN; P-GP; PEPT; PLASMA CLEARANCE RATE; VER; VERAPAMIL HYDROCHLORIDE;

ANIMALS; ANTIGENS, CD13; ANTINEOPLASTIC AGENTS; CACO-2 CELLS; CELL PROLIFERATION; CYCLOSPORINE; DOGS; HUMANS; IMMUNOLOGIC FACTORS; INTESTINAL ABSORPTION; INTESTINES; K562 CELLS; LEUCINE; MADIN DARBY CANINE KIDNEY CELLS; MALE; P-GLYCOPROTEIN; RATS, WISTAR; U937 CELLS; VERAPAMIL;

EID: 84883617702     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.08.010     Document Type: Article

References (36)

1. T. Bansal, G. Mishra, M. Jaggi, R.K. Khar, and S. Talegaonkar Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats Eur. J. Pharm. Sci. 36 2009 580 590
2. P.M. Chaudhary, and I.B. Roninson Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs J. Natl. Cancer Inst. 85 1993 632 639 (Pubitemid 23120508)
3. M.K. Degorter, C.Q. Xia, J.J. Yang, and R.B. Kim Drug transporters in drug efficacy and toxicity Annu. Rev. Pharmacol. Toxicol. 10 2012 249 273
4. R. Elsby, M. Gillen, C. Butters, G. Imisson, P. Sharma, V. Smith, and D.D. Surry The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672 Drug Metab. Dispos. 39 2011 275 282
5. K.M. Giacomini, S.M. Huang, D.J. Tweedie, L.Z. Benet, K.L. Brouwer, X. Chu, A. Dahlin, R. Evers, V. Fischer, K.M. Hillgren, K.A. Hoffmaster, T. Ishikawa, D. Keppler, R.B. Kim, C.A. Lee, M. Niemi, J.W. Polli, Y. Sugiyama, P.W. Swaan, J.A. Ware, S.H. Wright, S.W. Yee, M.J. Zamek-Gliszczynski, and L. Zhang Membrane transporters in drug development Nat. Rev. Drug Discov. 9 2010 215 236
6. M. Grujić, and M. Renko Aminopeptidase inhibitors bestatin and actinonin inhibit cell proliferation of myeloma cells predominantly by intracellular interactions Cancer Lett. 182 2002 113 119 (Pubitemid 34621173)
7. Y. Gu, G.J. Wang, X.L. Wu, Y.T. Zheng, J.W. Zhang, H. Ai, J.G. Sun, and Y.W. Jia Intestinal absorption mechanisms of ginsenoside Rh2: stereoselectivity and involvement of ABC transporters Xenobiotica 40 2010 602 612
8. P. He, and C.C. Yun Mechanisms of the regulation of the intestinal Na+/H+ exchanger NHE3 J. Biomed. Biotechnol. 2010 2010 238080
9. R. Hori, Y. Tomita, T. Katsura, M. Yasuhara, K. Inui, and M. Takano Transport of bestatin in rat renal brush-border membrane vesicles Biochem. Pharmacol. 45 1993 1763 1768 (Pubitemid 23150964)
10. S.M. Huang, R. Temple, D.C. Throckmorton, and L.J. Lesko Drug interaction studies: study design, data analysis, and implications for dosing and labeling Clin. Pharmacol. Ther. 81 2007 298 304 (Pubitemid 46174829)
11. L. Kagan, T. Dreifinger, D.E. Mager, and A. Hoffman Role of p-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats Drug Metab. Dispos. 38 2010 1560 1566
12. D. Krige, L.A. Needham, L.J. Bawden, N. Flores, H. Farmer, L.E. Miles, E. Stone, J. Callaghan, S. Chandler, V.L. Clark, P. Kirwin-Jones, V. Legris, J. Owen, T. Patel, S. Wood, G. Box, D. Laber, R. Odedra, A. Wright, L.M. Wood, S.A. Eccles, E.A. Bone, A. Ayscough, and A.H. Drummond CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells Cancer Res. 68 2008 6669 6679
13. Z. Liu, C. Wang, Q. Liu, Q. Meng, J. Cang, L. Mei, T. Kaku, and K. Liu Uptake, transport and regulation of JBP485 by PEPT1 in vitro and in vivo Peptides 32 2011 747 754
14. Liu, K.J.; He, J.H.; Su, X.D.; Sim, H.M.; Xie, J.D.; Chen, X.G.; Wang, F.; Liang, Y.J.; Singh, S.; Sodani, K.; Talele, T.T.; Ambudkar, S.V.; Chen, Z.S.; Wu, H.Y.; Fu, L.W.; 2012. Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo. Int. J. Cancer (doi: 10.1002/ijc.27649), in press.
15. B. Lkhagvaa, K. Tani, K. Sato, Y. Toyoda, C. Suzuka, and S. Sone Bestatin, an inhibitor for aminopeptidases, modulates the production of cytokines and chemokines by activated monocytes and macrophages Cytokine 44 2008 386 391
16. O. Lyass, B. Uziely, R. Ben-Yosef, D. Tzemach, N.I. Heshing, M. Lotem, G. Brufman, and A. Gabizon Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma Cancer 89 2000 1037 1047
17. C. Mawrin, C. Wolke, D. Haase, S. Krüger, R. Firsching, G. Keilhoff, W. Paulus, D.H. Gutmann, A. Lal, and U. Lendeckel Reduced activity of CD13/aminopeptidase N (APN) in aggressive meningiomas is associated with increased levels of SPARC Brain Pathol. 20 2010 200 210
18. T. Nakanishi, I. Tamai, A. Takaki, and A. Tsuji Cancer cell-targeted drug delivery utilizing oligopeptide transport activity Int. J. Cancer 88 2000 274 280
19. T. Ozben Mechanisms and strategies to overcome multiple drug resistance in cancer FEBS Lett. 580 2006 2903 2909 (Pubitemid 43729172)
20. S.W. Paine, A.J. Parker, P. Gardiner, P.J. Webborn, and R.J. Riley Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes Drug Metab. Dispos. 36 2008 1365 1374 (Pubitemid 351929321)
21. G.Y. Pan, G.J. Wang, X.D. Liu, J.P. Fawcett, and Y.Y. Xie The involvement of P-glycoprotein in berberine absorption Pharmacol. Toxicol. 91 2002 193 197 (Pubitemid 35216922)
22. T.J. Raub P-glycoprotein recognition of substrates and circumvention through rational drug design Mol. Pharm. 3 2006 3 25 (Pubitemid 43331747)
23. K. Sawafuji, Y. Miyakawa, E. Weisberg, J.D. Griffin, Y. Ikeda, and M. Kizaki Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways Leuk. Lymphoma. 44 2003 1987 1996 (Pubitemid 37369635)
24. A.H. Schinkel, and J.W. Jonker Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview Adv. Drug Deliv. Rev. 55 2003 3 29 (Pubitemid 36078452)
25. O.A. Scornik, and V. Botbol Cellular uptake of 3H-bestatin in tissues of mice after its intravenous injection Drug Metab. Dispos. 25 1997 798 804 (Pubitemid 27318598)
26. K. Sekine, H. Fujii, and F. Abe Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines Leukemia 13 1999 729 734 (Pubitemid 29243624)
27. F. Shen, S. Chu, A.K. Bence, B. Bailey, X. Xue, P.A. Erickson, M.H. Montrose, W.T. Beck, and L.C. Erickson Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells J. Pharmacol. Exp. Ther. 324 2008 95 102 (Pubitemid 350294163)
28. S. Shukla, S. Ohnuma, and S.V. Ambudkar Improving cancer chemotherapy with modulators of ABC drug transporters Curr. Drug Targets 12 2011 621 630
29. J. Smalley, A.M. Marino, B. Xin, T. Olah, and P.V. Balimane Development of a quantitative LC-MS/MS analytical method coupled with turbulent flow chromatography for digoxin for the in vitro P-gp inhibition assay J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci. 854 2007 260 267 (Pubitemid 46962390)
30. H. Sugimoto, S. Matsumoto, M. Tachibana, S. Niwa, H. Hirabayashi, N. Amano, and T. Moriwaki Establishment of in vitro P-glycoprotein inhibition assay and its exclusion criteria to assess the risk of drug-drug interaction at the drug discovery stage J. Pharm. Sci. 100 2011 4013 4023
31. R. Tian, N. Koyabu, H. Takanaga, H. Matsuo, H. Ohtani, and Y. Sawada Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates Pharm. Res. 19 2002 802 809 (Pubitemid 34686739)
32. J.W. Xu, C.G. Li, X.E. Huang, Y. Li, and J.G. Huo Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases Asian Pac. J. Cancer Prev. 12 2011 985 987
33. M. Yamashita, H. Kajiyama, M. Terauchi, K. Shibata, K. Ino, A. Nawa, S. Mizutani, and F. Kikkawa Involvement of aminopeptidase N in enhanced chemosensitivity to paclitaxel in ovarian carcinoma in vitro and in vivo Int. J. Cancer 120 2007 2243 2250 (Pubitemid 46555865)
34. T. Yasumitsu, S. Ohshima, N. Nakano, Y. Kotake, and S. Tominaga Bestatin in resected lung cancer. A randomized clinical trial Acta. Oncologica. 29 1990 827 831 (Pubitemid 20354537)
35. J. Zhang, C. Wang, Q. Liu, Q. Meng, J. Cang, H. Sun, Y. Gao, T. Kaku, and K. Liu Pharmacokinetic interaction between JBP485 and cephalexin in rats Drug Metab. Dispos. 38 2010 930 938
36. Y. Zhu, Q. Meng, C. Wang, Q. Liu, H. Sun, T. Kaku, and K. Liu Organic anion transporters involved in the excretion of bestatin in the kidney Peptides 33 2012 265 271